Hunan Er Kang Pharmaceutical (SHE:300267) — Stock Price
Hunan Er Kang Pharmaceutical (SHE:300267) is currently trading at CN¥3.29 CNY, up 1.54% today. Over the past 52 weeks, shares have ranged between CN¥2.88 and CN¥4.84. This page tracks Hunan Er Kang Pharmaceutical's live share price on the SHE exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Hunan Er Kang Pharmaceutical market capitalisation.
Hunan Er Kang Pharmaceutical (300267) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Hunan Er Kang Pharmaceutical's daily closing share price and trading volume on the SHE exchange over the past year, giving a clear view of recent price momentum and liquidity.
Hunan Er Kang Pharmaceutical Income Statement — Revenue, Profit & Earnings by Year
Hunan Er Kang Pharmaceutical's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | CN¥1.14 Billion | CN¥1.78 Billion | CN¥1.87 Billion | CN¥2.24 Billion | CN¥2.38 Billion |
| Cost of Revenue | CN¥825.96 Million | CN¥1.42 Billion | CN¥1.45 Billion | CN¥1.71 Billion | CN¥1.84 Billion |
| Gross Profit | CN¥313.65 Million | CN¥364.19 Million | CN¥415.64 Million | CN¥521.74 Million | CN¥542.70 Million |
| Research & Development | CN¥45.17 Million | CN¥57.44 Million | CN¥48.15 Million | CN¥49.02 Million | CN¥48.07 Million |
| SG&A | CN¥198.45 Million | CN¥269.51 Million | CN¥157.11 Million | CN¥186.96 Million | CN¥195.32 Million |
| Total Operating Expenses | CN¥1.19 Billion | CN¥1.87 Billion | CN¥1.85 Billion | CN¥2.18 Billion | CN¥2.23 Billion |
| Operating Income | CN¥-53.97 Million | CN¥-83.71 Million | CN¥19.69 Million | CN¥59.17 Million | CN¥151.59 Million |
| EBITDA | — | — | CN¥199.34 Million | CN¥-639.40 Million | CN¥407.97 Million |
| EBIT | — | — | CN¥19.69 Million | CN¥59.17 Million | CN¥81.92 Million |
| Interest Expense | CN¥8.68 Million | CN¥6.66 Million | CN¥5.50 Million | CN¥9.29 Million | CN¥12.16 Million |
| Income Before Tax | CN¥-388.12 Million | CN¥-198.93 Million | CN¥17.35 Million | CN¥-845.78 Million | CN¥211.69 Million |
| Income Tax Expense | — | — | CN¥-19.54 Million | CN¥-47.54 Million | CN¥20.41 Million |
| Net Income | CN¥-373.37 Million | CN¥-195.32 Million | CN¥45.76 Million | CN¥-791.20 Million | CN¥202.22 Million |
Hunan Er Kang Pharmaceutical Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Hunan Er Kang Pharmaceutical's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Assets | CN¥5.20 Billion | CN¥5.48 Billion | CN¥5.86 Billion | CN¥5.43 Billion | CN¥6.55 Billion |
| Total Current Assets | CN¥1.72 Billion | CN¥1.73 Billion | CN¥2.09 Billion | CN¥1.95 Billion | CN¥2.68 Billion |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | CN¥120.00 Million | CN¥118.60K | CN¥114.12 Million | — | CN¥5.30 Million |
| Net Receivables | CN¥103.18 Million | CN¥109.15 Million | CN¥133.69 Million | CN¥287.93 Million | CN¥353.79 Million |
| Inventory | CN¥600.78 Million | CN¥691.60 Million | CN¥821.34 Million | CN¥714.77 Million | CN¥756.06 Million |
| Property, Plant & Equipment | — | — | CN¥2.86 Billion | CN¥2.60 Billion | CN¥2.96 Billion |
| Goodwill | CN¥2.00 Million | CN¥2.00 Million | CN¥10.01 Million | CN¥10.01 Million | CN¥21.83 Million |
| Total Liabilities | CN¥797.54 Million | CN¥669.05 Million | CN¥804.57 Million | CN¥558.28 Million | CN¥753.22 Million |
| Total Current Liabilities | CN¥705.34 Million | CN¥603.30 Million | CN¥725.43 Million | CN¥498.93 Million | CN¥691.51 Million |
| Long-term Debt | — | — | — | — | — |
| Net Debt | — | — | — | — | — |
| Total Stockholder Equity | CN¥4.45 Billion | CN¥4.84 Billion | CN¥5.05 Billion | CN¥4.85 Billion | CN¥5.77 Billion |
| Retained Earnings | CN¥1.17 Billion | CN¥1.55 Billion | CN¥1.93 Billion | CN¥1.89 Billion | CN¥2.83 Billion |
Hunan Er Kang Pharmaceutical Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Hunan Er Kang Pharmaceutical generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | CN¥166.69 Million | CN¥148.42 Million | CN¥281.02 Million | CN¥92.68 Million | CN¥178.53 Million |
| Capital Expenditures | CN¥195.60 Million | CN¥238.19 Million | CN¥173.49 Million | CN¥349.33 Million | CN¥605.89 Million |
| Free Cash Flow | CN¥-28.91 Million | CN¥-89.77 Million | CN¥107.53 Million | CN¥-256.65 Million | CN¥-427.36 Million |
| Investing Cash Flow | — | — | CN¥-258.58 Million | CN¥-33.18 Million | CN¥-945.63 Million |
| Financing Cash Flow | — | — | CN¥-9.37 Million | CN¥-335.25 Million | CN¥341.66 Million |
| Dividends Paid | CN¥-8.42 Million | CN¥-70.10 Million | CN¥4.73 Million | CN¥114.92 Million | CN¥38.40 Million |
| Stock-Based Compensation | — | — | — | — | — |
| Depreciation | CN¥197.36 Million | CN¥204.29 Million | CN¥176.49 Million | CN¥197.09 Million | CN¥183.97 Million |
| Change in Cash | CN¥-20.73 Million | CN¥-122.30 Million | CN¥31.37 Million | CN¥-278.72 Million | CN¥-434.45 Million |
Hunan Er Kang Pharmaceutical Earnings History — EPS Actual vs. Analyst Estimates
Track Hunan Er Kang Pharmaceutical's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Sep 30, 2025 | 0.00 | — | — |
| Jun 30, 2025 | 0.00 | — | — |
| May 16, 2025 | 0.01 | — | — |
| Oct 25, 2024 | -0.02 | — | — |
| Aug 29, 2024 | 0.00 | — | — |
| May 17, 2024 | -0.11 | — | — |
| Oct 23, 2023 | -0.01 | — | — |
| Aug 28, 2023 | 0.01 | — | — |